The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
CEACAM1, a Novel Serum Biomarker for Pancreatic Cancer
Abstract
OBJECTIVES: Serum biomarkers for early diagnosis of pancreatic adenocarcinoma are not currently available. We recently observed elevated expression of CEACAM1 in pancreatic adenocarcinomas and sought to determine whether serum CEACAM1 levels were elevated in pancreatic cancer patients. METHODS: CEACAM1 messenger RNA levels were measured in pancreatic tissue samples using quantitative reverse transcription-polymerase chain reaction. CEACAM1 was localized by immunohistochemistry in adenocarcinomas and in pancreatic intraductal neoplasia lesions. CEACAM1 serum levels were assessed by a double determinant enzyme-linked immunosorbent assay and compared with serum levels of CA19-9. RESULTS: CEACAM1 had higher expression levels in pancreatic adenocarcinomas compared with noncancerous pancreas (P < 0.0001) and was localized to neoplastic cells (95% (45/47) of adenocarcinomas and 85% (17/20) of pancreatic intraductal neoplasia 3 lesions. CEACAM1 was expressed in the sera of 91% (74/81) of pancreatic cancer patients, 24% (15/61) of normal patients, and 66% (35/53) of patients with chronic pancreatitis, with a sensitivity and specificity superior to CA19-9. The combination of CEACAM1 and CA19-9 had significantly higher diagnostic accuracy than CA19-9. CONCLUSIONS: CEACAM1 is expressed in pancreatic adenocarcinoma, and serum levels of CEACAM1 serve as a useful indicator for the presence of pancreatic cancer. Additional validation studies on the use of serum CEACAM1 as a diagnostic marker in pancreatic cancer are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phases of Biomarker Development for Early Detection of Cancer
Pepe, M. S., Etzioni, R., Feng, Z., Potter, J. D., Thompson, M. L., Thornquist, M., Winget, M., & Yasui, Y. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.14.1054 · Cited by 1,686
Cited by
Beauchemin, N., & Arabzadeh, A. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9444-6 · Cited by 538
Combination of plasma microRNAs with serum CA19‐9 for early detection of pancreatic cancer
Liu, J., Gao, J., Du, Y., Li, Z., Ren, Y., Gu, J., Wang, X., Gong, Y., Wang, W., & Kong, X. (2012) · International Journal of Cancer · doi:10.1002/ijc.26422 · Cited by 309
Mayerle, J., Kalthoff, H., Reszka, R., Kamlage, B., Peter, E., Schniewind, B., González Maldonado, S., Pilarsky, C., Heidecke, C.-D., Schatz, P., et al. (2018) · Gut · doi:10.1136/gutjnl-2016-312432 · Cited by 307
A Compendium of Potential Biomarkers of Pancreatic Cancer
Harsha, H. C., Kandasamy, K., Ranganathan, P., Rani, S., Ramabadran, S., Gollapudi, S., Balakrishnan, L., Dwivedi, S. B., Telikicherla, D., Selvan, L. D. N., et al. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000046 · Cited by 288
Screening for Pancreatic Cancer: Why, How, and Who?
Poruk, K. E., Firpo, M. A., Adler, D. G., & Mulvihill, S. J. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e31825ffbfb · Cited by 249
Metadata
- Authors
- Simeone, D. M., Ji, B., Banerjee, M., Arumugam, T., Li, D., Anderson, M. A., Bamberger, A. M., Greenson, J., Brand, R. E., Ramachandran, V., & Logsdon, C. D.
- Venue
- Pancreas
- Published
- 2007-05
- Volume
- 34
- Issue
- 4
- Pages
- 436-443
- ISSN
- 0885-3177 (ISSN-L)
- OpenAlex
- W1989955153
- Cited by
- 161
- References
- 1
- FWCI
- 5.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CEACAM1, a Novel Serum Biomarker for Pancreatic Cancer. https://app.cochat.ai/papers/10.1097/mpa.0b013e3180333ae3
- The paper
- Simeone, D. M., Ji, B., Banerjee, M., Arumugam, T., Li, D., Anderson, M. A., Bamberger, A. M., Greenson, J., Brand, R. E., Ramachandran, V., & Logsdon, C. D. (2007). CEACAM1, a Novel Serum Biomarker for Pancreatic Cancer. Pancreas. https://doi.org/10.1097/mpa.0b013e3180333ae3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.